Versant Ventures commits $30m to Matterhorn Biosciences
Versant Ventures has launched Matterhorn Biosciences AG, a biotech company focused on developing T cell receptor therapies.
5 August 2020•1 min read
Versant Ventures has launched Matterhorn Biosciences AG, a biotech company focused on developing T cell receptor therapies.